Fresenius extends CFO contract: Fresenius stock is valued at EUR 25.2 billion

Published on 10/19/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 core net income rose 14.00 percent to EUR 470.00 million. Fresenius stock costs EUR 44.74 on October 19, 2026 after the EUR 45.08 Xetra close.

Leadership, earnings and valuation

Fresenius extended Sara Hennicken's contract through 2032 on October 15, 2026.
Second-quarter 2026 revenue rose 6.00 percent to EUR 5.864 billion.
Fresenius stock trades at EUR 44.74 at 10:05 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.75 percent below the Xetra close of October 16, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) was trading at EUR 44.74 at Lang & Schwarz on October 19, 2026, at 10:05 a.m. CEST, 0.75 percent below the EUR 45.08 Xetra close of October 16, 2026, while its market capitalization stood at EUR 25.2 billion. The latest company decision reshaped the leadership of Fresenius Kabi and extended the finance chief's mandate.

In an October 15, 2026 release, Fresenius said the Supervisory Board appointed Dr. Marc-Alexander Mahl to the Management Board effective November 1, 2026. Sara Hennicken's contract as chief financial officer was extended for another five years and will run through 2032.

Leadership changes set a 2032 marker

Mahl will take responsibility for the Fresenius Kabi businesses, while Hennicken continues to oversee finance, IT and cybersecurity. The arrangement gives the company continuity in finance and a defined transition for Kabi, where Pharma and Nutrition are being managed as separate growth priorities.

Why mAbxience still matters

On October 1, 2026, EQS News reported that Fresenius acquired the remaining 45.00 percent of mAbxience for up to EUR 750.0 million. The transaction gives Fresenius full ownership of its biosimilars platform and is expected to contribute immediately to adjusted earnings per share.

Fresenius' investor-relations page reported second-quarter 2026 revenue of EUR 5.864 billion, up 6.00 percent from EUR 5.571 billion a year earlier. Core net income rose 14.00 percent to EUR 470.0 million, while core earnings per share increased 14.00 percent to EUR 0.83. The figures point to stronger operating performance as management builds the next phase of its strategy. Fresenius published the figures and outlook on its investor-relations page.

Three milestones frame the story

Fresenius' dated company record links a EUR 1.0 billion bond issue on July 13, 2026, the sale of 7.8 million Fresenius Medical Care shares for around EUR 300.0 million on September 7, 2026, and the October 15, 2026 leadership changes. The sequence shows a company combining balance-sheet management, portfolio actions and executive continuity.

Which dates come next?

The next two scheduled dates are November 1, 2026, when Mahl joins the Management Board, and November 4, 2026, when Fresenius is scheduled to publish its third-quarter 2026 report. The first date comes from Fresenius; the reporting date is listed on the company's investor-relations page.

Valuation stays below the latest close

The current euro quote leaves Fresenius below the previous Xetra session's close, even as the company enters the next reporting cycle with a stronger second-quarter earnings profile and a settled finance leadership plan. The DAX-listed company remains focused on Kabi and Helios as its main operating businesses.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.